期刊文献+

川穹嗪联合倍他乐克对慢性心力衰竭的疗效观察 被引量:2

Objective To Observe Chuan Qiong Hydrochloride Combined with Metoprolol in the Treatment of Chronic Heart Failure
下载PDF
导出
摘要 目的:观察川穹嗪联合倍他乐克对慢性心力衰竭的治疗效果,指导临床用药。方法:68例慢性心力衰竭患者随机分为两组(对照组和治疗组),对照组给予倍他乐克治疗,治疗组采用川穹嗪和倍他乐克联合治疗。结果:治疗组的总有效率高于对照组(P<0.05),治疗组患者心功能改善情况优于对照组(P<0.05),治疗组患者血清炎症因子ICAM-1、TNF-α和CRP的水平明显低于对照组(P<0.05)。治疗期间,患者未发生严重不良反应。结论:川穹嗪和倍他乐克具有协同作用,两者联合治疗慢性心力衰竭疗效显著,安全可靠。 Objective:To observe Chuan Qiong hydroehloride combined with metoprolol in the treatment of chronic heart failure. Methods: 68 patients with chronic heart failure were randomly divided into two groups (control and treatment groups), the control group was given metoprolol treatment, the treatment group were treated with hydrochloride combined with metoprolol. Results : The total effective rate of control group was higher than trealment group(P 〈 0.05), improvement in cardiac function of treatment group was better than the control group(P 〈 0.05), serum inflammatory factors ICAM -- 1, TNF - α and CRP levels of treatment group were significantly lower than the control group(P 〈 0 05) . During treatment, patients with no serious adverse reactions. Conclusion: Chuan Qiong hydrochloride and metoprolol had synergistic effect, combination of the two in the treatment of chronic heart failure effect is significant, safe and reliable.
作者 白岭晓 宫梅
出处 《内蒙古医学杂志》 2011年第9期1037-1039,共3页 Inner Mongolia Medical Journal
关键词 川穹嗪 倍他乐克 慢性心力衰竭 Chuan qiong hydrochloride Metoprolol Chronic heart failure
  • 相关文献

参考文献5

二级参考文献4

共引文献347

同被引文献24

  • 1国家中医药管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:29.
  • 2中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2014,42(2):98-122.
  • 3Kitzman DW,Brubaker P,Morgan T,et al.Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction:A Randomized Clinical Trial[J].JAMA,2016,315(1):36-46.
  • 4Borovkova NJ,Kuznecova TE,Borovkov NN,et al.Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination[J].Kardiologiia,2015,55(6):22-26.
  • 5Grzywa-Celinska A,Dyczko M,Rekas-Wojcik A,et al.Ventilatory disorders in patients with chronic heart failure[J].Pol Merkur Lekarski,2015,39(232):248-250.
  • 6Zh D K,Pavlikova EP,Averkov OA,et al.First Experience of Clinical Application of LCZ696-an AT1-angiotensin Receptors and Neprilysin Inhibitor——in Patients With Chronic Heart Failure and Reduced Ejection Fraction[J].Kardiologiia,2015,55(7):14-25.
  • 7Turnbull IC,Karakikes I,Serrao GW,et al.Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium[J].FASEB J,2014,28(2):644-654.
  • 8Salzano A,Sirico D,Arcopinto M,et al.Anti remodeling therapy:new strategies and future perspective in post-ischemic heart failure.Part II[J].Monaldi Arch Chest Dis,2014,82(4):195-201.
  • 9Sirico D,Salzano A,Celentani D,et al.Anti remodeling therapy:new strategies and future perspective in post-ischemic heart failure:Part I[J].Monaldi Arch Chest Dis,2014,82(4):187-194.
  • 10Abraham WT,Stevenson LW,Bourge RC,et al.Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy:complete follow-up results from the CHAMPION randomised trial[J].Lancet,2016,387(10017):453-461.

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部